REVB: Development spending rose as cash runway fell short of one year
Meno di 1 minuto di lettura
Q3 and 9M operating expenses and losses increased YoY as development spending rose, led by GEM-AKI. Cash of $9.1M is not expected to fund operations for a year after issuance, making additional financing critical.
Original document: Revelation Biosciences, Inc. [REVB] SEC 10-Q Quarterly Report — Nov. 5 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr